| Malignant Mixed Mesodermal (Mullerian) Tumor studied in …STUDIED_INderived16 of 16show fewer |
|---|
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active) | — | — | Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active) | — | — | Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01737619NA · active not recruiting PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 16 trials mapped (9 active) | — | — | Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483048Phase 1 · recruiting MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer · condition mapped CURATED_BROADER · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05494580Phase 1/Phase 2 · completed Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639074Phase 2 · recruiting Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03641287NA · terminated The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03924245Phase 1 · terminated Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00989651Phase 1 · completed Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ALIAS · 16 trials mapped (9 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |